Drug intelligence / Profile preview

ACT-901

Development stage: Preclinical
Lead developer: Alpha Cancer Technologies
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
Administration: Unspecified

Overview

ACT-901 is a targeted cancer therapy in preclinical development that consists of a conjugate between alpha-fetoprotein (AFP) and paclitaxel. This drug is designed to deliver the chemotherapeutic agent paclitaxel directly to cancer cells by exploiting the presence of AFP receptors on tumor cells and myeloid-derived suppressor cells (MDSCs). The mechanism aims to increase efficacy while reducing off-target toxicity compared to conventional chemotherapy. Preclinical studies have demonstrated that ACT-901 can successfully target and kill cancer cells with minimal toxicity to healthy tissues. The drug is being developed primarily for solid and liquid tumors, with initial focus on ovarian and testicular germ cell cancers[2][6][8]. The developer is Alpha Cancer Technologies.

Other names: Third generation paclitaxel therapy

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on ACT-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT-901.

Explore the full profile